BOSTON – TRIA, a partner-led architecture firm with a focus on designing spaces for science, technology, and corporate clients, announced that it has been selected by Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., to design its Center for Genetics Guided Dementia Discovery (G2D2), a new exploratory drug research facility focused on human genetics-based immunodementia therapeutics.
Located in the newly constructed Alewife Research Center at 35 CambridgePark Drive in the bio-pharmaceutical hub of Cambridge, Mass., the new 50,000–square-foot lab and office facility is expected to be complete in mid-2019.
The new facility designed by TRIA will feature an open office plan and adjacent open laboratory for Eisai’s neuroscience R&D team of over 100 employees, which is set around a central collaboration meeting space dubbed “The Brain.” The site’s open labs are designed to allow multi-disciplinary scientists (including wet-lab chemistry, biology and automation) to work together in a single, accessible and shared lab space.
Collaboration zones are intermingled to create neighborhoods throughout the office, which offers bench seating, sit-to-stand desks, and personal lockers. Several huddle and conference rooms are scattered throughout the workspace, including two conference rooms with a movable wall that opens for larger gatherings. All meeting areas and tables are technology-enabled to offer flexibility and promote the impromptu sharing of ideas.
The Eisai project team includes:
- Architect: TRIA
- General Contractor: John Moriarty & Associates
- MEP/FP Engineers: AHA Consulting Engineers
- OPM: Black Diamond Real Estate Advisors
- Landlord: The Davis Companies
- Office Furniture: Office Resources and Knoll
- Lighting: Reflex Lighting.
